These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An introduction to adaptive designs and adaptation in CNS trials. Dragalin V Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739 [TBL] [Abstract][Full Text] [Related]
5. The use of ANAM to assess the side-effect profiles and efficacy of medication. Wilken JA; Sullivan CL; Lewandowski A; Kane RL Arch Clin Neuropsychol; 2007 Feb; 22 Suppl 1():S127-33. PubMed ID: 17116387 [TBL] [Abstract][Full Text] [Related]
6. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. Cole PE; Schwarz AJ; Schmidt ME Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072 [TBL] [Abstract][Full Text] [Related]
7. The role of pharmacogenetics in treating central nervous system disorders. Patnaik M; Renda MJ; Athanasiou MC; Reed CR Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543 [TBL] [Abstract][Full Text] [Related]
8. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders. Macauley D; Al-Shamahi A IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499 [No Abstract] [Full Text] [Related]
9. Is pharma running out of brainy ideas? Miller G Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165 [No Abstract] [Full Text] [Related]
10. Centrally acting drugs. Bateman DN; Chaplin S Br Med J (Clin Res Ed); 1988 Feb; 296(6619):417-9. PubMed ID: 3125927 [No Abstract] [Full Text] [Related]
11. Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. Hiyama T; Yoshihara M; Tanaka S; Haruma K; Chayama K J Gastroenterol Hepatol; 2009 Apr; 24(4):537-46. PubMed ID: 19220673 [TBL] [Abstract][Full Text] [Related]
13. [The interaction of drugs acting predominantly on the CNS]. Zelikson IuI; Davydova ON Med Sestra; 1988 Nov; 47(11):45-52. PubMed ID: 3221755 [No Abstract] [Full Text] [Related]
14. Challenges in the search for drugs to treat central nervous system disorders. Enna SJ; Williams M J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069 [TBL] [Abstract][Full Text] [Related]
15. Adult neurogenesis pharmacology in neurological diseases and disorders. Taupin P Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715 [TBL] [Abstract][Full Text] [Related]
16. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328 [No Abstract] [Full Text] [Related]
17. Drugs to treat Alzheimer's disease. J Psychosoc Nurs Ment Health Serv; 2009 Apr; 47(4):13-4. PubMed ID: 19437925 [No Abstract] [Full Text] [Related]
18. Multifunctional drugs as neurotherapeutics. Van der Schyf CJ; Youdim MB Neurotherapeutics; 2009 Jan; 6(1):1-3. PubMed ID: 19110194 [TBL] [Abstract][Full Text] [Related]
19. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases. Bishop KM Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711 [TBL] [Abstract][Full Text] [Related]
20. [On new mechanisms of action of centrally active drugs]. Castrén E; Panula P Duodecim; 2003; 119(15):1487-95. PubMed ID: 14502828 [No Abstract] [Full Text] [Related] [Next] [New Search]